YM BioSciences Announces Pivotal Preclinical Efficacy Data for the JAK1/2 inhibitor CYT387

News   Apr 21, 2010

 
YM BioSciences Announces Pivotal Preclinical Efficacy Data for the JAK1/2 inhibitor CYT387
 
 
 

RELATED ARTICLES

Concept Life Sciences and Alderley Analytical Partner to provide Bioanalytical and DMPK Services

News

Companies announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.

READ MORE

New Partnership to Provide Bioanalytical and DMPK Services

News

Concept Life Sciences, the integrated drug discovery, development and analytical services company, and Alderley Analytical, bioanalytical Contract Research Organisation (CRO), today announced they have signed a partnership agreement to provide high-value bioanalytical and DMPK study services.

READ MORE

All in a Droplet: Atomic Resolution of ALS Protein Resolved

News

Researchers have described atom-by-atom changes in a family of proteins linked to amyotrophic lateral sclerosis (ALS), a group of brain disorders known as frontotemporal dementia and degenerative diseases of muscle and bone.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE